Rimon Gold Assets Ltd 4
4 · Wize Pharma, Inc. · Filed Dec 31, 2020
Insider Transaction Report
Form 4
Rimon Gold Assets Ltd
10% Owner
Transactions
- Exercise of In-Money
Common Stock
2020-12-29+520,820→ 7,877,670 total - Exercise of In-Money
Common Stock
2020-12-29+3,385,212→ 7,385,060 total - Exercise of In-Money
Warrant (right to buy)
2020-12-29−3,385,212→ 0 totalExercise: $0.27Exp: 2024-12-12→ Common Stock (3,385,212 underlying) - Sale
Common Stock
2020-12-29−4,340→ 7,873,330 total - Exercise of In-Money
Warrant (right to buy)
2020-12-29−400,000→ 0 totalExercise: $0.16From: 2019-04-21Exp: 2023-10-23→ Common Stock (400,000 underlying) - Sale
Common Stock
2020-12-29−28,210→ 7,356,850 total - Sale
Common Stock
2020-12-29−3,077→ 3,999,848 total - Exercise of In-Money
Common Stock
2020-12-29+400,000→ 4,002,925 total - Exercise of In-Money
Common Stock
2020-12-29+350,334→ 7,522,996 total - Exercise of In-Money
Warrant (right to buy)
2020-12-29−520,820→ 0 totalExercise: $0.16From: 2019-05-31Exp: 2021-05-30→ Common Stock (520,820 underlying) - Sale
Common Stock
2020-12-29−2,919→ 7,520,077 total - Exercise of In-Money
Future Investment Rights
2020-12-29−350,334→ 0 totalExercise: $0.27From: 2019-12-13Exp: 2024-12-12→ Common Stock (350,334 underlying)
Footnotes (6)
- [F1]On December 23, 2020 the registrant has voluntary reduced the exercise price of warrants to $0.001. The reporting person exercised a warrant to purchase shares of the registrant's common stock for the reduced exercise price.
- [F2]On December 29, 2020 the reporting person exercised a warrant to purchase 400,000 shares of the registrant's common stock for $0.16 a share. The reporting person paid the exercise price on a cashless basis, resulting in the registrant withholding of 3,077 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 396,923 shares.
- [F3]On December 29, 2020 the reporting person exercised a warrant to purchase 3,385,212 shares of the registrant's common stock for $0.27 a share. The reporting person paid the exercise price on a cashless basis, resulting in the registrant withholding of 28,210 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 3,357,002 shares.
- [F4]On December 29, 2020 the reporting person exercised a warrant to purchase 520,820 shares of the registrant's common stock for $0.16 a share. The reporting person paid the exercise price on a cashless basis, resulting in the registrant withholding of 4,340 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 516,480 shares.
- [F5]On December 29, 2020 the reporting person exercised a warrant to purchase 350,334 shares of the registrant's common stock for $0.27 a share. The reporting person paid the exercise price on a cashless basis, resulting in the registrant withholding of 2,919 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 347,415 shares.
- [F6]Exercisable five days following the public announcement of positive clinical data results for LO2A.